Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

Fig. 3

Results of probabilistic sensitivity analyses for cost-effectiveness of add-on dapagliflozin to standard care versus standard care alone in Asia–Pacific countries under different country-specific willingness-to-pay thresholds. GDP per capita (2020): US$ 39,000 for Japan; US$ 30,000 for Korea; US$ 58,000 for Singapore; US$ 52,000 for Australia

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840